Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by PwC's Health Industries. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PwC's Health Industries or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Taking a closer look at the Most Favored Nation Pricing Executive Order

16:47
 
Share
 

Manage episode 486658465 series 3305757
Content provided by PwC's Health Industries. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PwC's Health Industries or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, and Phil Scalfani, PwC’s Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration’s executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead.
Discussion Highlights:

  • The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countries
  • Pharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroad
  • A proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)
  • Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developments

Speakers:

Glenn Hunzinger, Health Industries Leader, PwC
Philip Sclafani, Partner, Pharma & Life Sciences, PwC

Linked materials:

Most Favored Nation prescription drug pricing Executive Order

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

  continue reading

62 episodes

Artwork
iconShare
 
Manage episode 486658465 series 3305757
Content provided by PwC's Health Industries. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PwC's Health Industries or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Tune in as Glenn Hunzinger, PwC’s Health Industries Leader, and Phil Scalfani, PwC’s Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration’s executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead.
Discussion Highlights:

  • The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countries
  • Pharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroad
  • A proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)
  • Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developments

Speakers:

Glenn Hunzinger, Health Industries Leader, PwC
Philip Sclafani, Partner, Pharma & Life Sciences, PwC

Linked materials:

Most Favored Nation prescription drug pricing Executive Order

For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

  continue reading

62 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play